Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01127321 · ClinicalTrials.gov registry record · Phase 1
A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus
A Phase 1 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT01127321: Clinical Trial Phase 1 study, sponsored by MedImmune.
NCT01127321 is a Phase 1 study that was terminated before completion, run by MedImmune. The registered enrollment target is 44 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01127321, a Phase 1 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of MEDI-570 in adult subjects with moderately to severely active systemic lupus erythematosus (SLE).
Primary Outcome
An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug an
Interventions
- OTHER Placebo
- BIOLOGICAL MEDI-570 0.03 MG
- BIOLOGICAL MEDI-570 0.1 MG
- BIOLOGICAL MEDI-570 0.3 MG
- BIOLOGICAL MEDI-570 1 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Why NCT01127321 stopped before completion
NCT01127321 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01127321 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01127321 about?
NCT01127321 is a clinical study titled "A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus". The purpose of this study is to evaluate the safety and tolerability of MEDI-570 in adult subjects with moderately to severely active systemic lupus erythematosus (SLE).
What is the current status of trial NCT01127321?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2010-05. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01127321?
The interventions under investigation include: Placebo (OTHER), MEDI-570 0.03 MG (BIOLOGICAL), MEDI-570 0.1 MG (BIOLOGICAL), MEDI-570 0.3 MG (BIOLOGICAL), MEDI-570 1 MG (BIOLOGICAL).
Who is sponsoring clinical trial NCT01127321?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01127321's enrollment target sits among peer trials
44 1086th of 2000 higher than 901 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia